Litcius/Paper detail

Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial

Daniel J. Jackson, Leonard B. Bacharier, Peter J. Gergen, Lisa Gagalis, Agustin Calatroni, Stephanie Wellford, Michelle A. Gill, Jeffrey R. Stokes, Andrew H. Liu, Rebecca S. Gruchalla, Robyn T. Cohen, Melanie Makhija, Gurjit K. Khurana Hershey, George O'connor, Jacqueline A. Pongracic, Michael G. Sherenian, Katherine Rivera‐Spoljaric, Edward M. Zoratti, Stephen J. Teach, Meyer Kattan, Cullen M. Dutmer, Hae Jin Kim, Carin Lamm, William J Sheehan, R. Max Segnitz, Kimberly A. Dill‐McFarland, Cynthia M. Visness, Patrice M. Becker, James E. Gern, Christine A. Sorkness, William W. Busse, Matthew C. Altman

2022The Lancet148 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMepolizumabAsthmaExacerbationPlaceboPopulationPediatricsRandomized controlled trialWheezeInternal medicinePhysical therapyEosinophilAlternative medicinePathologyEnvironmental healthAsthma and respiratory diseasesDelphi Technique in ResearchHealth, Environment, Cognitive Aging
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial | Litcius